Cullinan Therapeutics, Inc.
NASDAQ:CGEMMedical - Pharmaceuticals
+$0.62 today
- Market cap
- $584.94M
- Beta
- 0.01
- P/E (TTM)
- -4.0
- EPS (TTM)
- -$3.73
Volume 1.06M
Average 0.99M
CGEM Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Cullinan Therapeutics, Inc.NASDAQ: CGEM
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin declines year over year
Q1 FY2026 selling, general & admin of $11.57M fell 14.5% year over year, behind the -5.2% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 6.0% from the prior quarter. Over 3 fiscal years it compounded at +10.5% a year.
Context
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 7 analysts of $4.28M (-92.1%) for the fiscal year ending Dec 2026, a slowdown from the +1.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $11.57M-6.0% QoQ
- Last fiscal yearDec 2025
- $54.25M+1.0% YoY
- LTMMar 2026
- $52.28M-5.2% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 54.25M USD
- Year-over-year change
- +1.0%
- 4-year CAGR
- +16.8%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 54.25M | +1.0% |
| FY2024 | 2024-12-31 | 53.71M | +26.4% |
| FY2023 | 2023-12-31 | 42.49M | +5.7% |
| FY2022 | 2022-12-31 | 40.19M | +37.9% |
| FY2021 | 2021-12-31 | 29.15M | — |
Selling, General & Admin vs competitors
How CGEM compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -5.2% is the 8th highest of 11, against a peer median of +7.8%.
- Over three fiscal years its annual growth of +10.5% compares with a peer median of +11.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $357.49M USD | +10.5% | +25.2% | 26.3% | |
| LTM Mar 2026 | $82.03M USD | +32.5% | — | 103.6% | |
| LTM Aug 2026 | $78.21M USD | +57.0% | +11.6% | 11.1% | |
| LTM Jun 2026 | $65.29M USD | +5.1% | +10.3% | 62.2% | |
| LTM Mar 2026 | €53.63M EUR | +14.4% | +12.3% | 143.8% | |
| LTM Mar 2026 | $52.28M USD | -5.2% | +10.5% | — | |
| LTM Mar 2026 | $42.56M USD | -1.1% | +23.3% | 196.9% | |
| LTM Mar 2026 | $38.15M USD | -27.9% | -12.7% | 24.3% | |
| LTM Mar 2026 | $27.19M USD | +59.1% | +55.2% | — | |
| LTM Mar 2026 | $21.28M USD | -23.4% | -6.3% | — | |
| LTM Mar 2026 | $9.36M USD | -6.3% | -5.7% | 12.9% | |
| Peer median (excluding CGEM) | — | +7.8% | +11.6% | 44.3% | |
Competitors are the stored peer set for CGEM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 18.94M | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 306K | 0 |
| Gross Profit | 18.94M | 0 | 0 | (306K) | 0 |
| Gross Margin | 100.0% | — | — | — | — |
| Research & Development | 57.75M | 91.95M | 148.16M | 142.9M | 187.4M |
| Selling, General & Admin | 29.15M | 40.19M | 42.49M | 53.71M | 54.25M |
| Operating Expenses | 86.9M | (144.65M) | 191.09M | 196.61M | 241.65M |
| Depreciation & Amortization | 53K | 93K | 310K | 306K | 311K |
| EBITDA | (67.43M) | (132.04M) | (190.34M) | (167.15M) | (219.57M) |
| EBITDA Margin | -356.0% | — | — | — | — |
| Operating Income | (67.95M) | 144.65M | (191.09M) | (196.92M) | (241.65M) |
| Operating Margin | -358.7% | — | — | — | — |
| Interest Income | 477K | 6.61M | 21.63M | 29.66M | 22.21M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 469K | 6.67M | 21.87M | 29.46M | 21.77M |
| Income Before Tax | (67.49M) | 151.32M | (169.22M) | (167.46M) | (219.88M) |
| Pre-Tax Margin | -356.3% | — | — | — | — |
| Income Tax Expense | 0 | 42.12M | (14.12M) | 117K | 0 |
| Net Income | (65.57M) | 111.21M | (153.16M) | (167.38M) | (219.88M) |
| Net Margin | -346.1% | — | — | — | — |
| EPS (Basic) | (1.48) | 2.46 | (3.69) | (3.11) | (3.72) |
| EPS (Diluted) | (1.48) | 2.38 | (3.69) | (3.11) | (3.72) |
| Weighted Avg Shares | 44.29M | 45.16M | 41.51M | 53.77M | 59.05M |
| Weighted Avg Shares (Diluted) | 44.29M | 46.64M | 41.55M | 53.77M | 59.05M |
Cullinan Therapeutics, Inc.
NASDAQ:CGEM
Intrinsic Alpha fair value
Locked
Current Price
$9.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.